slides · global inventory
Table
Component collection for the active corpus filters, with each row opening the slide detail view.
Matching slides 60,568
Current window 42,271-42,300
Pages 2,019
Rows per page 30
Component
42,271-42,300 of 60,568
04
Includes a footnote regarding a 1-for-25 reverse stock split.Aeglea BioTherapeutics | Investor Presentation Deck | 56 slides · Aeglea BioTherapeutics
Pitch deck Investor relations 1 hit
05
The slide uses a pipeline chart format to show the development status of seven different programs.Aeglea BioTherapeutics | Investor Presentation Deck | 56 slides · Aeglea BioTherapeutics
Pitch deck Investor relations 1 hit
13
The slide uses a Gantt-style pipeline visualization to show progress of seven distinct programs.Aeglea BioTherapeutics | Investor Presentation Deck | 56 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Agitate (Make it worse)Loop · Aha Moment1 hit
17
The slide uses a checkmark/arrow matrix to highlight competitive differentiation.Aeglea BioTherapeutics | Investor Presentation Deck | 56 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Solution (Provide relief)Loop · Aha Moment1 hit
18
The slide uses a standard antibody diagram to annotate specific engineering improvements.Aeglea BioTherapeutics | Investor Presentation Deck | 56 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Solution (Provide relief)Loop · Aha Moment1 hit
20
The chart shows dose-response curves for three donors; the table summarizes the calculated EC50 values.Aeglea BioTherapeutics | Investor Presentation Deck | 56 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Solution (Provide relief)1 hit
28
The table highlights the competitive positioning of SPY001, specifically emphasizing its subcutaneous administration profile.Aeglea BioTherapeutics | Investor Presentation Deck | 56 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Solution (Provide relief)Loop · Quick Win Big Bet1 hit
32
The slide uses a checkmark-based comparison matrix to highlight SPY002's superior profile.Aeglea BioTherapeutics | Investor Presentation Deck | 56 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Solution (Provide relief)1 hit
33
The slide uses an antibody diagram to annotate specific technical improvements (half-life extension and formulation).Aeglea BioTherapeutics | Investor Presentation Deck | 56 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Solution (Provide relief)1 hit
40
The slide uses a bar chart to illustrate the additive effect of combining two therapies, with a supporting table for N, maintenance remission, and safety.Aeglea BioTherapeutics | Investor Presentation Deck | 56 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Solution (Provide relief)1 hit
41
The slide uses a comparison framework to highlight the competitive advantage of Spyre's gut-selective approach.Aeglea BioTherapeutics | Investor Presentation Deck | 56 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Solution (Provide relief)1 hit
48
The slide uses a table-based timeline structure to map drug candidates (SPY001-004) against expected clinical milestones.Aeglea BioTherapeutics | Investor Presentation Deck | 56 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Impact & Next Steps1 hit
49
The slide uses a custom bar chart visualization within a table to show market cap ranges (Min, IPO, Today, Max).Aeglea BioTherapeutics | Investor Presentation Deck | 56 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Impact & Next Steps1 hit
50
The table maps historical M&A deal values to Spyre's internal pipeline milestones.Aeglea BioTherapeutics | Investor Presentation Deck | 56 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Impact & Next Steps1 hit
97
arm | IPO Presentation Deck | 117 slidesarm | IPO Presentation Deck | 117 slides · Arm
Pitch deck Investment bank 1 hit
19
The slide uses the term 'flywheel' in the title, though the content is a data table rather than a diagram.Freightos | Investor Presentation Deck | 33 slides · Freightos
Pitch deck Investor relations Loop · Quick Win Big Bet1 hit
22
The slide provides specific ranges for transactions, GBV, revenue, and adjusted EBITDA, along with year-over-year growth percentages.Freightos | Investor Presentation Deck | 33 slides · Freightos
Pitch deck Investor relations 1 hit
23
Includes logos of strategic shareholders: Qatar Airways, SGX, FedEx, IAG Cargo, and LATAM.Freightos | Investor Presentation Deck | 33 slides · Freightos
Pitch deck Investor relations 1 hit
27
Includes a footnote regarding non-recurring share-based listing expenses.Freightos | Investor Presentation Deck | 33 slides · Freightos
Pitch deck Investor relations 1 hit
09
The slide uses a comparison frame to contrast the negative outcomes of a standalone scenario with the positive outcomes of full integration.UBS | Results Presentation Deck | 41 slides · UBS
Conference presentation Investor relations Beat · Problem & ComplicationLoop · Before After1 hit
24
Excludes Credit Suisse; includes footnote regarding seasonal tax payments.UBS | Results Presentation Deck | 41 slides · UBS
Conference presentation Investor relations Beat · Impact & Next StepsLoop · Maturity Curve1 hit
25
Excludes Credit Suisse; includes YoY and QoQ growth metrics.UBS | Results Presentation Deck | 41 slides · UBS
Conference presentation Investor relations Beat · Impact & Next StepsLoop · Maturity Curve1 hit
26
Excludes Credit Suisse; includes specific footnotes regarding gains on sale.UBS | Results Presentation Deck | 41 slides · UBS
Conference presentation Investor relations Beat · Impact & Next StepsLoop · Maturity Curve1 hit
27
Excludes Credit Suisse. Includes specific commentary on Global Markets and Global Banking performance drivers.UBS | Results Presentation Deck | 41 slides · UBS
Conference presentation Investor relations Beat · Solution & ApproachLoop · Maturity Curve1 hit
29
Includes a waterfall chart for pre-tax income and a summary table of revenues and expenses.UBS | Results Presentation Deck | 41 slides · UBS
Conference presentation Investor relations Beat · Solution & Approach1 hit
34
The 2Q23 column is highlighted with a grey background, likely to emphasize the most recent quarter.UBS | Results Presentation Deck | 41 slides · UBS
Conference presentation Investor relations 1 hit
35
The table highlights the impact of the Credit Suisse acquisition on the group's financial performance metrics.UBS | Results Presentation Deck | 41 slides · UBS
Conference presentation Investor relations 1 hit
22
The table includes both absolute dollar values (in thousands) and percentage margins for each line item.Vivid Seats | Investor Presentation Deck | 22 slides · Vivid Seats
Pitch deck Investor relations 1 hit
10
Includes a non-GAAP financial measure disclaimer.Vivid Seats | Results Presentation Deck | 19 slides · Vivid Seats
Conference presentation Investor relations Beat · FinancialsLoop · Why Now1 hit
19
The table provides a breakdown of various adjustments including tax, interest, D&A, transaction costs, and equity-based compensation, with detailed footnotes explaining each line item.Vivid Seats | Results Presentation Deck | 19 slides · Vivid Seats
Conference presentation Investor relations 1 hit